MINT-DICLOFENAC SOLUTION

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

DICLOFENAC SODIUM

Disponible des:

MINT PHARMACEUTICALS INC

Codi ATC:

S01BC03

Designació comuna internacional (DCI):

DICLOFENAC

Dosis:

0.1%

formulario farmacéutico:

SOLUTION

Composición:

DICLOFENAC SODIUM 0.1%

Vía de administración:

OPHTHALMIC

Unidades en paquete:

5ML/10ML

tipo de receta:

Prescription

Área terapéutica:

NONSTEROIDAL ANTI-INFLAMMATORY AGENTS

Resumen del producto:

Active ingredient group (AIG) number: 0114417004; AHFS:

Estat d'Autorització:

APPROVED

Data d'autorització:

2018-04-27

Fitxa tècnica

_ _
_ _
_Page 1 of 24_
PRODUCT MONOGRAPH
PR
MINT-DICLOFENAC
Diclofenac Sodium Ophthalmic Solution
0.1% w/v
(House Standard)
Anti-inflammatory Analgesic Agent
Mint Pharmaceuticals Inc.
1093 Meyerside Drive, Unit 1
Mississauga, Ontario
L5T 1J6
www.mintpharmaceuticals.com
Date of Preparation:
April 26, 2018
Submission Control No: 200405
_ _
_ _
_ _
_Page 2 of 24_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................7
OVERDOSAGE
..................................................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
..............................................................8
STORAGE AND STABILITY
............................................................................................9
SPECIAL HANDLING INSTRUCTIONS
.........................................................................9
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................9
PART II: SCIENTIFIC INFORMATION
...............................................................................10
PHARMACEUTICAL INFORMATION
..........................................................................10
CLINICAL TRIALS
.............